Fig. 2.

Endogenous IL-15 participates in the therapeutic activity of CD40 agonism. (A) Schematic of the treatment of mice bearing orthotopic MB49 bladder tumors with anti-CD40 antibody and/or anti-IL-15 blocking antibody or isotype-matched control antibody. (B) Representative intravital luciferase imaging (Left) and quantification of luminescence (Center) and bladder weights (Right) across mice at day 12 post-tumor implantation (n = 5 mice per group; bars represent SD). (C) Representative flow cytometry plots and quantification across mice (n = 5 mice per group) of CD44^hiCD122⁺ CD8 T cells (Top) and CXCR6⁺CD44^hiCD122⁺ CD8 T cells (Bottom) in the bladders of mice treated as outlined in A. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.